Mast Cell Activation Syndrome, Histamine & Women’s Health: The Hidden Links Between Hormones, Bladder Pain & Period Flares

For many women, unexplained symptoms such as chronic pelvic pain, bladder pressure, urinary urgency, digestive disturbances, flushing, headaches and fatigue can feel like a confusing puzzle. Symptoms may fluctuate throughout the menstrual cycle, intensify before a period or worsen after particular foods, stress or environmental exposures. When multiple body systems are affected, it can be difficult to identify a common thread.

One possible contributor in some people is mast cell activation syndrome (MCAS), a condition involving inappropriate or excessive activation of mast cells, immune cells that help regulate inflammation and allergic responses. These cells release substances including histamine, prostaglandins, leukotrienes and tryptase, which can affect tissues throughout the body.

Histamine and mast cell activity are also being investigated in relation to women’s hormonal health and bladder pain conditions, including bladder pain syndrome (BPS) and interstitial cystitis (IC). Although these conditions can overlap, they are not interchangeable, and MCAS is not an established explanation for every case of chronic pelvic or bladder pain.

Understanding the potential connections can help women recognise patterns, seek appropriate assessment and explore evidence-based treatment options.

What Is Mast Cell Activation Syndrome?

Mast cells are found throughout the body, particularly in the skin, respiratory tract, gastrointestinal tract, blood vessels and tissues surrounding nerves. They play an important role in immune defence and wound healing. When activated, they release chemical mediators that influence inflammation, blood vessel permeability, smooth muscle activity and sensory nerve signalling.

In MCAS, mast cells activate inappropriately and release mediators that cause recurrent symptoms affecting multiple organ systems. These may include flushing, itching, hives, abdominal cramping, diarrhoea, light-headedness, a racing heart, breathing difficulties and, in severe cases, anaphylaxis. However, experiencing several unexplained symptoms does not automatically mean someone has MCAS. This distinction matters because many other conditions can produce similar symptoms. Allergies, gastrointestinal disorders, autonomic dysfunction, medication reactions and other inflammatory or pain conditions may need to be considered. MCAS is also distinct from systemic mastocytosis, a condition involving an abnormal accumulation of mast cells in tissues. Although the conditions can share symptoms, they have different diagnostic criteria and clinical implications.

Histamine: More Than an Allergy Chemical

Histamine is one of the best-known substances released by mast cells. It is also produced by other cells and acts as a signalling molecule throughout the body. Histamine binds to four main receptor types, known as H1, H2, H3 and H4. Their effects vary depending on the tissue involved. Histamine can contribute to itching, flushing, swelling, stomach acid production, changes in blood vessel function and the transmission of sensory signals. Mast cell mediators can influence the gastrointestinal tract, pelvic tissues and nervous system. In susceptible individuals, this may contribute to symptoms such as abdominal discomfort, diarrhoea, pelvic sensitivity or urinary discomfort. Nevertheless, these symptoms are not specific to histamine excess, and there is no single symptom or routine blood test that independently establishes a diagnosis of MCAS. Histamine intolerance is another term sometimes used in discussions of food-related symptoms. It is not synonymous with MCAS, and its diagnostic methods and underlying mechanisms remain less firmly established. A reaction to a histamine-rich food, for example, does not necessarily indicate a mast cell disorder.

Why Women’s Hormones May Matter

Oestrogen and progesterone fluctuate throughout the menstrual cycle and influence immune function, inflammatory signalling and the tissues of the reproductive and urinary systems. Researchers have investigated interactions between sex hormones and mast cells, including evidence that oestrogen can influence mast cell activation in certain experimental settings (Jensen et al., 2010).  This provides a plausible biological reason why some women may notice symptom changes around ovulation or menstruation. In the days before menstruation, changing hormone concentrations coincide with changes in prostaglandin production and inflammatory signalling. Prostaglandins help drive uterine contractions and contribute to menstrual pain. For some women, this period can coincide with increased headaches, gastrointestinal symptoms, skin reactions or pelvic discomfort.

The menstrual cycle may also influence established pain conditions independently of MCAS. Endometriosis, migraine, irritable bowel syndrome and bladder pain syndrome can all exhibit cyclical symptom patterns.  It is therefore important not to assume that every premenstrual flare is caused by histamine. Hormonal changes, inflammatory mediators, pelvic floor muscle tension, nerve sensitisation and coexisting conditions may all contribute.

The Bladder, Histamine and Mast Cells

The bladder is more than a storage organ. Its lining, immune cells, sensory nerves and surrounding muscles work together to regulate filling, emptying and the sensation of needing to urinate.  Mast cells have been studied in bladder inflammation and chronic pelvic pain because they can release mediators that affect nearby nerves, blood vessels and tissues. Histamine may influence sensory signalling, while other mast cell mediators can contribute to inflammatory responses. In theory, these processes could increase bladder sensitivity and contribute to urgency, discomfort or pain in some individuals. However, the presence of bladder symptoms does not prove that mast cell activation is responsible. Research has identified mast cell involvement in subsets of people with bladder pain conditions, but findings are inconsistent. Mast cell numbers and activity are not sufficiently specific to diagnose MCAS or interstitial cystitis on their own. For women experiencing urinary frequency, urgency, bladder pressure or pain that persists despite negative urine cultures, a broader assessment is important. Urinary tract infections, pelvic floor dysfunction, endometriosis, overactive bladder and other urological or gynaecological conditions may need to be investigated.

Bladder Pain Syndrome and Interstitial Cystitis

Bladder pain syndrome (BPS), often called interstitial cystitis/bladder pain syndrome (IC/BPS), describes a chronic condition involving unpleasant sensations perceived to be related to the bladder, accompanied by lower urinary tract symptoms, such as urgency or frequency, when infection and other identifiable causes have been excluded. Symptoms vary. Some women experience pain as the bladder fills, with temporary relief after urination. Others report persistent pelvic pressure, urethral discomfort, pain during sexual activity or frequent trips to the toilet, including overnight. The causes of IC/BPS are not fully understood. Proposed mechanisms include changes in the bladder lining, inflammation, altered sensory nerve signalling, pelvic floor dysfunction and central nervous system sensitisation. Different mechanisms may be more important in different patients (Clemens et al., 2022). Mast cells and histamine have received attention because they may contribute to inflammatory signalling and nerve sensitivity in some cases. However, IC/BPS is a heterogeneous condition, and it should not be described simply as a histamine disorder. Some patients may benefit from antihistamines as part of an individualised treatment plan, but this does not establish that histamine is the primary cause of their symptoms. Treatment should be guided by a clinician familiar with bladder pain conditions and the patient's overall health. Importantly, a normal urine culture does not mean bladder pain is imagined or insignificant. Persistent symptoms deserve proper assessment and management even when routine tests do not reveal a clear cause.

Why Bladder Symptoms May Flare Around a Period

For women with IC/BPS, pelvic pain or suspected mast cell-related symptoms, menstruation can be a particularly difficult time. Some report worsening bladder pressure, urgency, frequency or pain in the days before bleeding begins or during menstruation.  Several overlapping mechanisms may explain these flares.  First, hormonal fluctuations may influence inflammatory signalling and pain perception. Second, prostaglandins released during menstruation contribute to uterine contractions and may intensify pelvic pain. Third, pelvic organs share nerve pathways, meaning pain originating in one area can influence sensitivity in another. This is one reason bladder and gynaecological symptoms can overlap. Pelvic floor muscles may also tighten in response to pain, increasing pressure and discomfort around the bladder and urethra. Over time, persistent pain can amplify the nervous system's response to otherwise ordinary sensations. For women with endometriosis, lesions affecting the bladder or nearby pelvic structures can cause cyclical urinary symptoms. Endometriosis should therefore be considered when bladder pain consistently worsens around menstruation, particularly when accompanied by severe period pain, painful sex, painful bowel movements or difficulty conceiving. Histamine and mast cell activity may be part of the picture for some individuals, but current evidence does not establish menstrual bladder flares as a reliable marker of MCAS. Cycle-related patterns are useful clinical information, not a diagnosis in themselves.

Treatment and Support

For confirmed MCAS, clinicians may consider trigger management and medications directed at particular mediators, such as H1 or H2 antihistamines, or other specialist-directed therapies. Treatment should be individualised, especially when multiple medications or medical conditions are involved. For IC/BPS, management may include education, individualised bladder and pain strategies, pelvic floor physiotherapy when muscle tenderness or dysfunction is present, appropriate oral medications and selected bladder-directed treatments. The American Urological Association emphasises tailoring treatment to the individual's presentation and reassessing approaches that are ineffective (Clemens et al., 2022). When symptoms worsen around menstruation, clinicians may also investigate dysmenorrhoea, endometriosis and other gynaecological causes. Hormonal treatment may help some conditions, but its suitability depends on the diagnosis, reproductive goals and individual risks.

A coordinated approach involving primary care, urology, gynaecology, allergy or immunology, and pelvic health physiotherapy can be particularly helpful when symptoms span several systems. Seek urgent medical care for possible anaphylaxis, including breathing difficulty, throat or tongue swelling, collapse or rapidly progressing symptoms. New severe pelvic pain, fever, visible blood in the urine or inability to urinate also warrants prompt medical assessment.

References

Clemens, J. Q., Erickson, D. R., Varela, N. P., & Lai, H. H. (2022). Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. The Journal of Urology, 208(1), 34–42. https://doi.org/10.1097/JU.0000000000002756 

Jensen, F., Woudwyk, M., Teles, A., Woidacki, K., Taran, F., Costa, S. D., & Zenclussen, A. C. (2010). Estradiol and progesterone regulate the migration of mast cells from the periphery to the uterus and induce their maturation and degranulation. PLoS ONE, 5(12), Article e14409. https://doi.org/10.1371/journal.pone.0014409 

Valent, P., Akin, C., Bonadonna, P., Broesby-Olsen, S., Brockow, K., Butterfield, J. H., Castells, M., Hartmann, K., Gotlib, J., Kluin-Nelemans, H. C., Kneidinger, M., Komarow, H. D., Lange, M., Metcalfe, D. D., Orfao, A., Pardanani, A., Reiter, A., Ruskova, A., Schwaab, J., ... Triggiani, M. (2019). Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome (MCAS). The Journal of Allergy and Clinical Immunology: In Practice, 7(4), 1125–1133. https://doi.org/10.1016/j.jaip.2019.01.006 

Valent, P., Akin, C., Hartmann, K., Alvarez-Twose, I., Brockow, K., Hermine, O., ... Metcalfe, D. D. (2021). Updated diagnostic criteria and classification of mast cell disorders: A consensus proposal. HemaSphere, 5(11), Article e646. https://doi.org/10.1097/HS9.0000000000000646 

Theoharides, T. C., Kempuraj, D., Vakali, S., & Sant, G. R. (2001). Mast cell involvement in interstitial cystitis: A review of human and experimental evidence. Urology, 57(6 Suppl. 1), 47–55.